Solventum Corporation (SOLV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SOLV SEC filings page.
Solventum Corporation (SOLV) reported $8.3B in revenue over the twelve months to Jun 30, 2026, down 0.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Profit recovered sharply in FY2025, but nearly flat sales and weak cash conversion reveal dependence on balance-sheet changes.
The profit-to-cash gap widened in FY2025: net income reached$1.56B while operating cash flow fell to$369M . With capital spending of$379M , free cash flow was-$10M , so reported earnings did not become deployable cash.
Revenue was nearly unchanged at
Equity expanded to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Solventum Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Solventum Corporation has an operating margin of 26.2%, meaning the company retains $26 of operating profit per $100 of revenue. This strong profitability earns a score of 69/100, reflecting efficient cost management and pricing power. This is up from 12.6% the prior year.
Solventum Corporation's revenue grew a modest 0.9% year-over-year to $8.3B. This slow but positive growth earns a score of 33/100.
Solventum Corporation has a moderate D/E ratio of 1.00. This balance of debt and equity financing earns a leverage score of 37/100.
Solventum Corporation's current ratio of 1.23 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
While Solventum Corporation generated $369.0M in operating cash flow, capex of $379.0M consumed most of it, leaving -$10.0M in free cash flow. This results in a low score of 54/100, reflecting heavy capital investment rather than weak cash generation.
Solventum Corporation earns a strong 30.8% return on equity (ROE), meaning it generates $31 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 77/100. This is up from 16.2% the prior year.
Solventum Corporation scores 2.28, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Solventum Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Solventum Corporation generates $0.24 in operating cash flow ($369.0M OCF vs $1.6B net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Solventum Corporation earns $6.29 in operating income for every $1 of interest expense ($2.2B vs $347.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Solventum Corporation generated $2.2B in revenue in Q2 2026. This represents an increase of 2.2% from the same quarter a year earlier. Against the prior quarter it is up 10.1%.
Solventum Corporation's EBITDA was $307.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.0% from the same quarter a year earlier. Against the prior quarter it is up 42.1%.
Solventum Corporation reported $92.0M in net income in Q2 2026. This represents an increase of 2.2% from the same quarter a year earlier. Against the prior quarter it is up 607.7%.
Solventum Corporation earned $0.53 per diluted share (EPS) in Q2 2026. This represents an increase of 3.9% from the same quarter a year earlier. Against the prior quarter it is up 657.1%.
Cash & Balance Sheet
Solventum Corporation generated $144.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 144.1% from the same quarter a year earlier. Against the prior quarter it is up 152.7%.
Solventum Corporation held $403.0M in cash against $4.6B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Solventum Corporation's gross margin was 58.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.6 percentage points.
Solventum Corporation's operating margin was 8.2% in Q2 2026, reflecting core business profitability. This is down 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.
Solventum Corporation's net profit margin was 4.2% in Q2 2026, showing the share of revenue converted to profit. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.
Solventum Corporation's ROE was 1.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
Capital Allocation
Solventum Corporation invested $178.0M in research and development in Q2 2026. This represents a decrease of 5.8% from the same quarter a year earlier. Against the prior quarter it is down 5.8%.
Solventum Corporation spent $288.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is up 329.9%.
Solventum Corporation invested $83.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 24.5% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.
SOLV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B+2.2% | $2.0B-3.0% | $2.0B-3.7% | $2.1B+0.7% | $2.2B+3.8% | $2.1B+2.7% | $2.1B+1.9% | $2.1B+0.4% |
| Gross Profit | $1.3B+9.4% | $1.1B-1.5% | $1.0B-8.2% | $1.1B-2.6% | $1.2B+3.3% | $1.1B-4.9% | $1.1B-3.4% | $1.2B-3.6% |
| R&D Expenses | $178.0M-5.8% | $189.0M-2.1% | $174.0M-12.6% | $183.0M-3.2% | $189.0M-1.6% | $193.0M-1.0% | $199.0M+4.7% | $189.0M+5.0% |
| SG&A Expenses | $927.0M+20.1% | $827.0M+7.5% | $759.0M-3.2% | $780.0M+11.3% | $772.0M+10.1% | $769.0M+29.0% | $784.0M+26.9% | $701.0M+33.5% |
| Operating Income | $181.0M-15.4% | $81.0M-46.7% | $125.0M-8.1% | $1.7B+514.5% | $214.0M-12.3% | $152.0M-60.1% | $136.0M-66.5% | $275.0M-45.4% |
| EBITDA | $307.0M-7.0% | $216.0M-23.1% | $255.0M-15.3% | $1.8B+351.0% | $330.0M-10.8% | $281.0M-46.0% | $301.0M-46.2% | $400.0M-37.6% |
| Interest Expense | $64.0M-37.9% | $62.0M-40.4% | $51.0M-52.3% | $89.0M-16.8% | $103.0M-9.6% | $104.0M+166.7% | $107.0M | $107.0M |
| Income Tax | $15.0M+15.4% | $3.0M+103.0% | -$5.0M+70.6% | $248.0M+451.1% | $13.0M+85.7% | -$99.0M-207.6% | -$17.0M-114.3% | $45.0M+12.5% |
| Net Income | $92.0M+2.2% | $13.0M-90.5% | $63.0M+103.2% | $1.3B+937.7% | $90.0M+1.1% | $137.0M-42.2% | $31.0M-88.6% | $122.0M-73.5% |
| EPS (Basic) | $0.53+1.9% | $0.07-91.1% | $0.36+100.0% | $7.26+937.1% | $0.52+2.0% | $0.79-42.3% | $0.18-88.5% | $0.70-73.7% |
| EPS (Diluted) | $0.53+3.9% | $0.07-91.0% | $0.35+94.4% | $7.22+931.4% | $0.510.0% | $0.78-43.1% | $0.18-88.5% | $0.70-73.7% |
| Diluted Shares (Avg) | 173M-1.1% | 176M+0.4% | N/A | 175M+0.9% | 175M+1.0% | 175M+1.2% | N/A | 174M+0.7% |
Not reported in any period shown, so not listed: Cost of Revenue.
SOLV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.2B-5.5% | $14.1B-3.0% | $14.3B-1.1% | $14.0B-5.2% | $15.1B+3.4% | $14.5B-1.3% | $14.5B+3.7% | $14.7B |
| Current Assets | $3.7B+16.6% | $3.6B+17.4% | $3.9B+18.8% | $4.4B+31.4% | $3.2B-4.6% | $3.1B-9.1% | $3.2B+29.0% | $3.4B |
| Cash & Equivalents | $403.0M-18.1% | $561.0M+5.1% | $878.0M+15.2% | $1.6B+112.7% | $492.0M-45.2% | $534.0M-46.4% | $762.0M+292.8% | $772.0M+1738.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.0B+8.1% | $1.1B+25.8% | $1.1B+10.5% | $1.0B+10.1% | $962.0M+7.0% | $866.0M-3.9% | $965.0M+12.6% | $953.0M |
| Accounts Receivable | $1.3B+23.0% | $1.1B+14.4% | $1.0B-1.0% | $1.0B-7.8% | $1.1B+3.6% | $926.0M-24.1% | $1.0B-20.5% | $1.1B |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $5.6B+6.7% | $5.6B+12.7% | $5.7B-10.6% | $5.3B-20.2% | $5.3B-18.2% | $5.0B-22.8% | $6.4B-2.4% | $6.6B |
| Total Liabilities | $9.4B-17.4% | $9.1B-19.0% | $9.2B-19.6% | $9.0B-22.2% | $11.4B-2.4% | $11.3B+3.7% | $11.5B+405.0% | $11.6B |
| Current Liabilities | $3.7B+39.8% | $3.3B+30.4% | $3.1B+16.0% | $2.9B+1.2% | $2.6B+1.9% | $2.6B+38.4% | $2.7B+56.4% | $2.9B |
| Non-Current Liabilities | $5.8B-34.4% | $5.8B-33.5% | $6.1B-30.5% | $6.0B-30.1% | $8.8B-3.6% | $8.7B-3.4% | $8.8B+1502.0% | $8.6B |
| Long-Term Debt | $4.6B-41.5% | $4.6B-41.4% | $5.0B-35.5% | $5.1B-34.2% | $7.8B-5.9% | $7.8B-5.9% | $7.8B | $7.8B |
| Total Equity | $4.8B+31.7% | $5.0B+52.3% | $5.0B+70.6% | $5.0B+56.2% | $3.6B+27.1% | $3.3B-15.3% | $3.0B-74.6% | $3.2B-72.4% |
| Retained Earnings | $1.9B+306.4% | $1.8B+378.8% | $1.8B+642.6% | $1.7B+721.8% | $468.0M+425.8% | $378.0M | $242.0M | $211.0M |
SOLV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $227.0M+34.3% | -$189.0M-751.7% | $95.0M-56.6% | $76.0M-55.0% | $169.0M-52.4% | $29.0M-93.4% | $219.0M-60.0% | $169.0M-65.7% |
| Depreciation & Amortization | $126.0M+8.6% | $135.0M+4.7% | $117.0M-22.0% | $114.0M-8.8% | $116.0M-7.9% | $129.0M-7.2% | $150.0M+7.9% | $125.0M-8.8% |
| Stock-Based Compensation | $38.0M+11.8% | $51.0M+4.1% | N/A | $41.0M+51.9% | $34.0M-39.3% | $49.0M+1125.0% | N/A | $27.0M+350.0% |
| Capital Expenditures | $83.0M-24.5% | $84.0M-22.9% | $63.0M-50.4% | $97.0M+4.3% | $110.0M+89.7% | $109.0M+6.9% | $127.0M+44.3% | $93.0M+40.9% |
| Free Cash Flow | $144.0M+144.1% | -$273.0M-241.3% | $32.0M-65.2% | -$21.0M-127.6% | $59.0M-80.1% | -$80.0M-123.5% | $92.0M-80.0% | $76.0M-82.2% |
| Investing Cash Flow | -$87.0M+20.9% | -$77.0M+32.5% | -$745.0M-486.6% | $3.8B+4149.5% | -$110.0M-89.7% | -$114.0M-11.8% | -$127.0M-44.3% | -$93.0M-1450.0% |
| Financing Cash Flow | -$300.0M-172.7% | -$50.0M+64.0% | -$115.0M-10.6% | -$2.7B-1233.2% | -$110.0M+72.2% | -$139.0M-130.1% | -$104.0M+66.0% | -$202.0M+58.4% |
| Share Buybacks | $288.0M | $67.0M | N/A | N/A | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
SOLV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.2%+3.9pp | 54.7%+0.8pp | 51.4%-2.5pp | 54.1%-1.8pp | 54.4%-0.3pp | 53.8%-4.3pp | 53.9%-2.9pp | 56.0%-2.3pp |
| Operating Margin | 8.2%-1.7pp | 4.0%-3.3pp | 6.3%-0.3pp | 80.6%+67.4pp | 9.9%-1.8pp | 7.3%-11.6pp | 6.6%-13.4pp | 13.2%-11.1pp |
| Net Margin | 4.2%0.0pp | 0.7%-6.0pp | 3.1%+1.7pp | 60.4%+54.5pp | 4.2%-0.1pp | 6.6%-5.1pp | 1.5%-11.9pp | 5.9%-16.3pp |
| Return on Equity | 1.9%-0.6pp | 0.3%-3.9pp | 1.3%+0.2pp | 25.4%+21.6pp | 2.5%-0.6pp | 4.2%-1.9pp | 1.1%-1.3pp | 3.8%-0.2pp |
| Return on Assets | 0.7%0.0pp | 0.1%-0.9pp | 0.4%+0.2pp | 9.1%+8.2pp | 0.6%0.0pp | 0.9%-0.7pp | 0.2%-1.7pp | 0.8% |
| Current Ratio | 1.02-0.2x | 1.07-0.1x | 1.230.0x | 1.50+0.3x | 1.22-0.1x | 1.19-0.6x | 1.20-0.3x | 1.16 |
| Debt-to-Equity | 0.95-1.2x | 0.92-1.5x | 1.00-1.6x | 1.03-1.4x | 2.14-0.8x | 2.40+0.2x | 2.64+2.6x | 2.45 |
| Asset Turnover | 0.160.0x | 0.140.0x | 0.140.0x | 0.150.0x | 0.140.0x | 0.140.0x | 0.140.0x | 0.14 |
| FCF Margin | 6.5%+3.8pp | -13.6%-9.7pp | 1.6%-2.8pp | -1.0%-4.7pp | 2.7%-11.5pp | -3.9%-20.7pp | 4.4%-18.1pp | 3.6%-16.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Solventum Corporation SOLV | FY2025 | $8.3B | $1.6B | 18.7% | $14.7B | 50/100 |
| Baxter International Inc. BAX | FY2025 | $11.2B | -$957.0M | -8.5% | $12.8B | 36/100 |
| Hologic Inc HOLX | FY2025 | $4.1B | $565.7M | 13.8% | $17.0B | 69/100 |
| The Cooper Companies, Inc. COO | FY2025 | $4.1B | $374.9M | 9.2% | $10.6B | 59/100 |
| West Pharmaceutical Services, Inc. WST | FY2025 | $3.1B | $493.7M | 16.1% | $25.9B | 76/100 |
| ResMed Inc. RMD | FY2026 | $5.7B | $1.5B | 26.9% | $33.0B | 87/100 |
Where Solventum Corporation Ranks
Frequently Asked Questions
What is Solventum Corporation's annual revenue?
Solventum Corporation (SOLV) reported $8.3B in total revenue for fiscal year 2025. This represents a 0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Solventum Corporation's revenue growing?
Solventum Corporation (SOLV) revenue grew by 0.9% year-over-year, from $8.3B to $8.3B in fiscal year 2025.
Is Solventum Corporation profitable?
Yes, Solventum Corporation (SOLV) reported a net income of $1.6B in fiscal year 2025, with a net profit margin of 18.7%.
What is Solventum Corporation's EBITDA?
Solventum Corporation (SOLV) had EBITDA of $2.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Solventum Corporation have?
As of fiscal year 2025, Solventum Corporation (SOLV) had $878.0M in cash and equivalents against $5.0B in long-term debt.
What is Solventum Corporation's gross margin?
Solventum Corporation (SOLV) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Solventum Corporation's operating margin?
Solventum Corporation (SOLV) had an operating margin of 26.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Solventum Corporation's net profit margin?
Solventum Corporation (SOLV) had a net profit margin of 18.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Solventum Corporation's return on equity (ROE)?
Solventum Corporation (SOLV) has a return on equity of 30.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Solventum Corporation's free cash flow?
Solventum Corporation (SOLV) recorded an outflow of $10.0M in free cash flow during fiscal year 2025. This represents a -101.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Solventum Corporation's operating cash flow?
Solventum Corporation (SOLV) generated $369.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Solventum Corporation's total assets?
Solventum Corporation (SOLV) had $14.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Solventum Corporation's capital expenditures?
Solventum Corporation (SOLV) invested $379.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Solventum Corporation spend on research and development?
Solventum Corporation (SOLV) invested $739.0M in research and development during fiscal year 2025.
What is Solventum Corporation's current ratio?
Solventum Corporation (SOLV) had a current ratio of 1.23 as of fiscal year 2025, which is considered adequate.
What is Solventum Corporation's debt-to-equity ratio?
Solventum Corporation (SOLV) had a debt-to-equity ratio of 1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Solventum Corporation's return on assets (ROA)?
Solventum Corporation (SOLV) had a return on assets of 10.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Solventum Corporation's P/E ratio?
Solventum Corporation (SOLV) trades at 10.2x earnings, its market capitalization divided by net income of $1.4B net income, trailing 12 months to June 30, 2026. The market capitalization is $14.7B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Solventum Corporation's price-to-sales ratio?
Solventum Corporation (SOLV) trades at 1.8x sales, its market capitalization divided by revenue of $8.3B revenue, trailing 12 months to June 30, 2026. The market capitalization is $14.7B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Solventum Corporation's Altman Z-Score?
Solventum Corporation (SOLV) has an Altman Z-Score of 2.28, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Solventum Corporation's Piotroski F-Score?
Solventum Corporation (SOLV) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Solventum Corporation's earnings high quality?
Solventum Corporation (SOLV) has an earnings quality ratio of 0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Solventum Corporation cover its interest payments?
Solventum Corporation (SOLV) has an interest coverage ratio of 6.29x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Solventum Corporation?
Solventum Corporation (SOLV) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.